Management Strategies for HER2 Posi4ve Metasta4c Breast Cancer
|
|
- Phillip Taylor
- 5 years ago
- Views:
Transcription
1 Management Strategies for HER2 Posi4ve Metasta4c Breast Cancer Karen A Gelmon MD FRCPC Professor Medicine University of Bri4sh Columbia Medical Oncologist, BC Cancer Agency Head, Division of Medical Oncology, UBC
2 COI Boards Susan G Komen Scien4fic Advisory Board OICR Scien4fic Advisory Board Breast Interna4onal Group Execu4ve Board Pharmaceu4cal Company Associa4ons Advisory Boards AstraZeneca, Roche, Novar4s, Pfizer, Oncotheryon, Nanostring, Merck Research Funding Pfizer, AstraZeneca, Novar4s, BMS
3 Our priori4es within cancer control Support the Patient Journey Facilitate Prevention / Early Detection Encourage Research Promote Optimal Performance Cancer Preven*on & Healthy Lifestyle Cancer Screening Cancer Treatment, Care Delivery and Follow Up Quality of Life: Survivorship Through End of Life Well Being C U R E Improve Information & Access
4 HER2+ Disease: Major Clinical Advances Trastuzumab Approved 2002 Three Large Adjuvant Trials Reported Lapa*nib Approved Preopera4ve Trials of Dual Blockade Pertuzumab Approved For MBC 2013 Pertuzumab Approved For neoadj in US 1998 First Preopera4ve Trials Reported Paving The Way For Use in Early Stage Disease Ini4al Trials of T-DM1, Nera4nib T-DM1 Approved Development of DUAL BLOCKADE as a strategy to increase impact
5 Milestones in the Management of HER2-posi4ve Advanced Breast Cancer Abbrevia4ons: Ana, anastrozole; Cape, capecitabine; CT, chemotherapy; Doc, docetaxel; Lap, lapa4nib; Let, letrozole; OS, overall survival; Pac, paclitaxel; Pert, pertuzumab; T-DM1, trastuzumab emtansine; Tras, trastuzumab. 5
6 Hazard Rate of Relapse (HRR) by subtype Cohort 1 ( ) vs Cohort 2 ( ) N= 7178 (3589 in each cohort) Cossef et al, JCO 2015
7 HER2 Posi4ve MBC The problem Despite high response rates, almost all pa4ents eventually develop progressive disease Can we improve up-front therapy and increase survival? Combined signal blockade Can we avoid current issues CNS disease Resistance Toxicity Are there pa4ents who are cured and can stop therapy? Are there very responsive pa4ents who can be treated with simple therapy
8 Mul4-target Strategies in HER2 Therapy An4 HER2 plus chemotherapy An4 HER2 plus hormone therapy An4 HER2 plus an4 angiogeneic agents Dual HER 2 blockade HER2 plus an mtor inhibitor Novel new HER2 agents Other targets such as Hsp-90, PI3K agents, CDK4/6 agents, checkpoint inhibitors, etc Vaccines
9 Trastuzumab and Pertuzumab Bind to Different Regions on HER2 and Have Synergis4c Ac4vity HER2 receptor Trastuzumab Subdomain IV of HER2 Trastuzumab suppresses HER2 ac*vity Flags cells for destruc*on by the immune system Dimerisa4on domain of HER2 9
10 Trastuzumab and Pertuzumab Bind to Different Regions on HER2 and Have Synergis4c Ac4vity Trastuzumab HER2 receptor Pertuzumab Dimerisa4on domain of HER2 Subdomain IV of HER2 Trastuzumab suppresses HER2 ac*vity Flags cells for destruc*on by the immune system Pertuzumab inhibits HER2 heterodimeriza*on Suppresses mul*ple HER signaling pathways Flags cells for destruc*on by the immune system 10
11 BO17929 Pertuzuamb and Trastuzumab in HER2 Posi4ve Advanced Cancer Progressing on Trastuzumab 1. Gelmon KA, et al. J Clin Oncol. 2008;26(May 20 suppl): Abstract Baselga J, et al J Clin Oncol, Baselga et al Cancer Res 2009, Cortes et al JCO 2012
12 CLEOPATRA Study Design HER2-positive MBC centrally confirmed (N = 808) 1:1 n = 406 Placebo + trastuzumab Docetaxel* 6 cycles Pertuzumab + trastuzumab PD PD n = 402 Docetaxel* 6 cycles Randomization stratified by geographic region and neo/adjuvant chemotherapy Study dosing q3w: Pertuzumab/placebo: 840 mg loading 420 mg maintenance Trastuzumab: 8 mg/kg loading 6 mg/kg maintenance Docetaxel: 75 mg/m mg/m 2 escalation if tolerated * < 6 cycles allowed for unacceptable toxicity or PD; > 6 cycles allowed at inves4gator discre4on. HER2, human epidermal growth factor receptor 2; MBC, metasta4c breast cancer; PD, progressive disease. Baselga J, et al. N Engl J Med 2012; 366:
13 Progression Free Survival Inves&gator-Assessed PFS (%) Ptz + T + D: median 18.7 months Pla + T + D: median 12.4 months Time (months) Δ 6.3 months HR % CI = 0.58, 0.80 p < n at risk Ptz + T + D Pla + T + D ITT popula4on. Stra4fied by geographic region and neo/adjuvant chemotherapy. 13
14 Final Overall Survival Analysis Median follow-up 50 months (range 0 70 months) OS (%) n at risk Ptz + T + D Pla + T + D HR % CI = 0.56, 0.84 p = Time (months) months Δ 15.7 months Ptz + T + D Pla + T + D 56.5 months ITT popula4on. Stra4fied by geographic region and neo/adjuvant chemotherapy. CI, confidence interval; Pla, placebo; Ptz, pertuzumab
15 CLEOPATRA: Toxicity and PFS in Pa4ents with Prior Trastuzumab Diarrhea 20% increase in all grades to 67%, 8% grade 3 Febrile neutropenia Grade 3: 14 vs 7.6% Rash All grades: 34 vs 24% Baselga et al, 2011; Swain et al, 2015
16 Pertuzumab: Key Clinical Ques4ons Is the use of pertuzumab standard in the first-line sefng? YES What chemotherapy partners are acceptable? For now, docetaxel and paclitaxel (less evidence) Velvet trial (vinorelbine) What about the pa4ent who missed out on firstline pertuzumab? Probably reasonable, but label is currently restricted to the first line secng Should pertuzumab be given beyond progression on P? NO, but a quesgon to test in clinical trial(s)
17 Con4nued HER2 Blockade Aser Progression on Trastuzumab Improves Outcome Author Agents N TTP PFS OS Von Minckwitz, et al Capecitabine + trastuzumab vs capecitabine months vs 5.6 months, P =.03 NR 25.5 months vs 20.4 months P =.257 Geyer, et al Capecitabine + lapa*nib vs capecitabine months vs 4.4 months, P< months vs 4.1 months, P< months vs 16 months P =.206 Blackwell, et al Lapa*nib + trastuzumab vs lapa*nib 291 NR 11.1 weeks vs 8.1 weeks, P = months vs 9.5 months, P =.026 TTP, time to progression Blackwell K, et al. J Clin Oncol. 2012:30(21): Cameron D, et al. Oncologist. 2010:15(9): Geyer CE, et al. N Engl J Med. 2006;355(26): Von Minckwitz G, et al. J Clin Oncol. 2009:27(12):
18 T-DM1 and Pertuzumab Mechanisms of Ac4on T-DM1 HER3 Antibody: Trastuzumab HER2 HER2 HRG Cytotoxic: DM1 PI3K Stable linker: MCC p85 Lysosome Pertuzumab p110 HER3 HER2 HRG PI3K p85 p110 DM1 Survival Prolifera*on Nucleus Nucleus Nucleus An4body-drug conjugate Induces cell death by inhibi4ng microtubule polymeriza4on 1 Inhibits HER2 signaling 2 Ac4vates ADCC 2 Inhibits HER2 shedding 2 HER2/HER3 dimeriza4on inhibitor Inhibits ligand-dependent HER2 dimeriza4on and signaling 3 Ac4vates ADCC 4 1. Lewis Phillips, Cancer Res 2008; 2. Junttila, Breast Cancer Res Treat 2010; 3. Baselga, Nature Rev Cancer 2009; 4. Scheuer, Cancer Res 2009.
19 HER2-positive, recurrent locally advanced breast cancer or MBC (N=137) First line setting Phase II Randomized Open Label Study 1:1 Trastuzumab 8 mg/kg loading dose; 6 mg/kg q3w IV + Docetaxel 75 or 100 mg/m 2 q3w (n=70) T-DM1 3.6 mg/kg q3w IV (n=67) PD a PD a Crossover to T-DM1 (optional) Stra4fica4on factors: World region, prior adjuvant trastuzumab therapy, disease-free interval Primary end points: PFS by inves4gator assessment, and safety Data analyses were based on clinical data cut of Nov 15, 2010 prior to T-DM1 crossover Key secondary end points: OS, ORR, DOR, CBR, and QOL Demographics imbalanced: 29 vs 34 % stage IV at diagnosis, 27 vs 18% exposed to prior trastuzumab, 40 vs 33% exposed to prior taxanes a Patients were treated until PD or unacceptable toxicity. b This was a hypothesis generating study; the final PFS analysis was to take place after 72 events had occurred. Hurvitz et al, JCO 2013
20 EMILIA Study Design 1:1 T-DM1 3.6 mg/kg q3w IV Capecitabine 1000 mg/m 2 orally bid, days 1 14, q3w + Lapatinib 1250 mg/day orally qd PD PD Stratification factors: World region, number of prior chemo regimens for MBC or unresectable LABC, presence of visceral disease Primary end points: PFS by independent review, OS, and safety Key secondary end points: PFS by investigator, ORR, duration of response, time to symptom progression Verma et al, NEJM 2012
21 Progression-Free Survival by Independent Review Median (mos) No. events Cap + Lap T-DM Stratified HR=0.650 (95% CI, 0.55, 0.77) P< No. at risk by independent review: Cap + Lap T-DM Unstratified HR=0.66 (P<0.0001).
22 Overall Survival: Confirmatory Analysis Data cut-off July 31, 2012; Unstratified HR=0.70 (P=0.0012).
23 ORR and DOR in Pa4ents with Measurable Disease Patients, % Objective response rate (ORR) Difference: 12.7% (95% CI, 6.0, 19.4) P= % 120/389 Cap + Lap 43.6 % 173/397 T- DM1 1.0 Proportion progressionfree No. at risk Cap + Lap T-DM1 Duration of response (DOR) Median, months (95% CI) Cap + Lap 6.5 (5.5, 7.2) T-DM (8.4, 20.8) Time (months)
24 Adverse Events Grade 3 AEs With Incidence 2% Cap + Lap (n=488) T-DM1 (n=490) Adverse Event All Grades, % Grade 3, % All Grades, % Grade 3, % Diarrhea Hand-foot syndrome Vomiting Asian patients Cap + Lap (n=86 ; 17%) Neutropenia Hypokalemia Fatigue Nausea Mucosal inflammation Thrombocytopenia Increased AST Increased ALT Anemia ALT, alanine aminotransferase; AST, aspartate aminotransferase. Updated with package insert, trastuzumab emtansine T-DM1 (n=94; 19%) Grade > 3 thrombocytopenia 1.3% 45.1%
25 Differen4al Toxicity in Asian Pa4ents? Median number of regimens for MBC: 3 (range 1-8)
26 Management of Toxicity Transaminase eleva4on Self-limited Persistent throughout course of therapy Generally does not require specific management Thrombocytopenia No need to check mid-cycle labs Hold and consider dose reduc4on for grade 3+ toxicity (<75K) on day of treatment start.
27 Exposure to TDM1 and Survival in EMILIA Highest quar*le lowest quar*le Wang J et al, Clin Pharmacol Ther, 2014
28 TH3RESA: A Phase III Trial of T-DM1 vs TPC HER2-posi*ve (central) advanced BC a (N=600) 2 T-DM1 3.6 mg/kg q3w IV (n=404) PD 2 prior HER2-directed therapies for advanced BC Prior treatment with trastuzumab, lapa*nib, and a taxane 1 Treatment of physician s choice (TPC) b (n=198) PD T-DM1 c (optional crossover) Stra*fica*on factors: World region, number of prior regimens for advanced BC, d presence of visceral disease Co-primary endpoints: PFS by inves4gator and OS Key secondary endpoints: ORR by inves4gator and safety a Advanced BC includes MBC and unresectable locally advanced/recurrent BC. b TPC could have been single-agent chemotherapy, hormonal therapy, or HER2-directed therapy, or a combina4on of a HER2-directed therapy with a chemotherapy, hormonal therapy, or other HER2-directed therapy. c First pa4ent in: Sep Study amended Sep 2012 (following EMILIA 2nd interim OS results) to allow pa4ents in the TPC arm to receive T-DM1 aser documented PD. d Excluding single-agent hormonal therapy. BC, breast cancer; IV, intravenous; ORR, objec4ve response rate; PD, progressive disease; q3w, every 3 weeks. Krop Lancet Oncology
29 OS: Analysis s*ll early 44 vs 61 events, HR 0.552, p= (14.9 vs NE) Stopping boundary HR<0.363 or P< Less toxic than standard op*ons More costly PFS benefit of 3 months Including in comparison with trastuzumab beyond progression
30 Response to subsequent therapy aser T-DM1 Maximum decrease in tumor diameter (%) Pa4ents had median of 7 prior lines of therapy prior to T-DM1 Median 4me on post-tdm1 therapy was 5.5 months Olson E M et al. Ann Oncol 2012;23:93-97
31 Are there alterna&ves to chemotherapy/pertuzumab in the first line and to TDM1 in the second line?
32 Randomized Controlled Trial Comparing Taxane-Based Chemotherapy with Lapa4nib or Trastuzumab as First-Line Therapy for Women with HER2+ Metasta4c Breast Cancer: MA.31 Pa*ent Popula*on HER2+ MBC Newly diagnosed or ajer failure of adjuvant therapy No CNS mets confirmed by MRI/CT Stra*fica*on Factors Prior (neo)adjuvant HER2 targeted therapy Prior (neo)adjuvant taxane chemo Taxane on study Liver metastases Randomize Lapa*nib + taxane* x 24 weeks Trastuzumab + taxane* x 24 weeks Lapa*nib un*l PD *Pacitaxel 80 mg/m 2 q wk on a 4-wk schedule or docetaxel 75 mg/m 2 q 3 wk at inves*gator s discre*on. radiological assessment, including head CT/MRI Trastuzumab un*l PD Primary objec*ve: PFS (NI followed by superiority) Secondary objec*ves: OS, 4me to/incidence of CNS mets at first PD, ORR, CBR, safety, biomarkers, QoL, health economics, pharmacogene4cs Gelmon et al, JCO 2014
33 Progression Free Survival Centrally-confirmed HER2+ Analysis Median PFS TTAX/T= 13.7 months Median PFS LTAX/L = 9.0 months HR = 1.48 (95% CI = ), P = TTAX/T LTAX/L # TTAX/T # LTAX/L Gelmon et al, ASCO 2012
34 MARIANNE Study Design HER2-posi*ve (central) LABC a or MBC No prior chemotherapy for LABC/ MBC >6 months from prior neo-/adjuvant vinca alkaloid or taxane chemotherapy N = 1095 Trastuzumab + docetaxel (8 mg/kg LD then 6 mg/kg or 75 mg/m 2 q3w) OR Trastuzumab + paclitaxel (4 mg/kg LD then 2 mg/kg + 80 mg/m 2 qw) T-DM1 + placebo b (3.6 mg/kg mg LD then 420 mg q3w) T-DM1 + pertuzumab (3.6 mg/kg mg LD then 420 mg q3w) Stra*fica*on factors: World region, Prior neo-/adjuvant therapy (if Yes: prior trastuzumab/lapa4nib), Visceral disease Primary end point: PFS by independent review facility (IRF), non-inferiority and superiority assessed Key secondary end points: OS, PFS by inves4gator, ORR, Safety, Pa4ent-reported outcomes LD, Loading dose. a Locally progressive or recurrent and not amenable to resection with curative intent; b Pertuzumab placebo.
35 Overall Survival (First Interim Analysis) Survival (%) No. at Risk HT T-DM1 T-DM1+P Time (mo.) HT T-DM1 T- DM1+P Median OS NR NR NR (mo.) Events (no.) Stra*fied HR (97.5% CI) vs HT 0.86 ( ) 0.82 ( ) HT T-DM1 T-DM1+P NR, not reached.
36 Randomized Phase II Study of T-DM1 + capecitabine in HER2- posi4ve MBC pa4ents progressing aser trastuzumab-based therapy (TRAX HER2) Cohorts 1 and 2 1,2 HER2-posi4ve MBC progressing aser trastuzumab T-DM1 Cohort 3 3 T-DM1 plus capecitabine Primary objec4ves efficacy (response rate + stabilisa4on of disease = CBR) 3. Baselga et al. Cancer Res. 2009;69(Suppl): Abstract Completed accrual in Spring 2016 MBC, metasta4c breast cancer; CBR, clinical benefit rate
37 HER2 targeted therapy adds modestly to endocrine therapy Addi4on of HER2-directed therapy improves PFS but not OS Endocrine therapy + HER2-directed therapy can be considered for select 1 st line pts with MBC (e.g. asymptoma4c, low burden disease, pts at increased risk of toxicity from chemotherapy)? No data on later lines
38 HER2 targeted therapy adds modestly to endocrine therapy Anastrozole vs Anastrozole + Trastuzumab Kaufman et al, JCO 2008 Letrozole vs Letrozole + Lapa4nib Johnston et al, JCO 2009
39 Treatment Approach For Pa4ent Presen4ng With HER2+ MBC in 2016 First Line: Taxane + Trastuzumab + Pertuzumab Second Line: TDM-1 Third, Fourth, Fifth, Sixth Line: Capecitabine + Lapatinib or Trastuzumab Vinorelbine + Trastuzumab Lapatinib + Trastuzumab Pertuzumab + Trastuzumab (?? if no prior Pertuzumab) Other chemotherapy + Trastuzumab?Everolimus/Trastuzumab/vinorelbine/ Endocrine Therapy + Trastuzumab Neratinib plus? capecitabine Clinical trial of new agents including immune modulators
40 CNS Disease Common 25 35% of metasta4c HER2 posi4ve cases Solitary mets removal and RT Whole brain, Stereotac4c RT Restaging if only brain mets con4nue systemic therapy, if progressive systemic disease change therapy Issue of op4mal treatment for HER2+ with brain mets Con4nued trastuzumab - Dawood Capecitabine plus lapa4nib? Or trastuzumab + cap? CEREBEL study Sugges4on of response with other agents including TDM1 ONT 380 -TKI with increased brain ac4ity
41 Progression-free survival (PFS) and (B) overall survival (OS) in the intent-to-treat popula4on in CEREBEL Study. Xavier Pivot et al. JCO doi: /jco by American Society of Clinical Oncology
42 EMILIA OS in Pa4ents with CNS Mets at Baseline Krop I, et al. Abstract P SABCS,2013
43 Case Series: CNS response with TDM-1 Results: Median brain metastasis free survival 11 mo. PR: 44.4% SD: 22.2% Conclusions: This prospec4ve case series again indicates that systemic therapy offers ac4vity in Her2-posi4ve BM T-DM1 offers relevant clinical ac4vity; therefore, the role of T-DM1 in BM should be inves4gated in larger studies. Bartsch et al, J Neurooncol 2014 Pre-T-DM1 Post-T-DM1
44 New HER2-directed agents Class HER2-targeted TKI HER2-targeted liposome Trifunc4onal an4body HER2 vaccine/ Checkpoint inhibitors PI3-kinase inhibitors/ mtor CDK 4/6 inhibitors Example(s) Nera4nib, afa4nib, ONT 380 (ARRY-380) MM-302 Ertumaxomab AE37 GDC-0032, BYL-719 everolimus Palbo, Abemaciclib
45 Simultaneous blockade of the HER2 pathway HER2 HER3 VEGF an4her2 + mtor inhib. AKT PI3K PTEN RAS RAF Cell membrane mtor MEK p27 Cyclin D Cyclin E MAPK Nucleus CDK 4/6 CDK 2 G1 S
46 BOLERO-3: Study Design N = 572* Locally advanced or metasta4c HER2 + breast cancer Prior taxane required TRAS resistance Adjuvant: progression on or within 12 months of TRAS Metasta4c: progression within 4 weeks of TRAS Measurable disease only Randomize 1:1 Stra4fica4on by prior lapa4nib use (yes/no) Everolimus (5 mg PO daily) + Vinorelbine (25 mg/m 2 weekly) + TRAS (2 mg/kg week ) (n = 284) Placebo (PO daily) + Vinorelbine (25 mg/m 2 weekly) + TRAS (2 mg/kg weekly*) (n = 285) Therapy un*l PD or intolerable toxicity Endpoints: Primary: PFS Secondary: OS, ORR, 4me to deteriora4on of ECOG PS, safety, DoR, CBR, and QoL * Actual enrollment was 569. Following a 4-mg/kg loading dose on day 1, cycle 1 (1 cycle = every 21 days). Abbrevia4ons: CBR, clinical benefit rate; DoR, Dura4on of response; ECOG, Eastern Coopera4ve Oncology Group; HER2, human epidermal growth factor receptor 2; ORR, overall response rate; OS overall survival; PD, progressive disease; PFS, progressive-free survival; PO, oral; PS, performance status; QoL, quality of life. h p:// 46 O Regan R, et al. ASCO 2013; Abstract 505. Not for distribu4on. Andre et al, Lancet Oncol 2014
47 BOLERO-3: Primary Endpoint Progression-Free Survival by Local Assessment Probability, % Hazard ratio = 0.78; 95% CI [0.65, 0.95] Log-rank P value =.0067 Median PFS Everolimus: 7.00 months; 95% CI [6.74, 8.18] Placebo: 5.78 months; 95% CI [5.49, 6.90] Censoring times Everolimus (n/n = 196/284) Placebo (n/n = 219/285) Time, weeks Number of Pa*ents S*ll at Risk Everolimus Placebo Abbrevia4ons: CI, confidence interval. 47 O Regan R, et al. ASCO 2013; Abstract 505. Not for distribu4on. Andre et al, Lancet Oncol 2014
48 BOLERO-1/TRIO 019: Study Design N = 719 Locally advanced or metastatic HER2+ breast cancer No prior therapy for advanced or metastatic disease (except endocrine therapy) Prior (neo)adjuvant trastuzumab and/or chemotherapy allowed 1 Measurable disease or presence of bone lesions (lytic or mixed) Randomized 2:1 Stratification factors: Prior neo/adjuvant TRAS Visceral metastases Everolimus (10 mg PO daily) + w Paclitaxel + Trastuzumab Placebo + w Paclitaxel + Trastuzumab Endpoints Primary: PFS (investigator-assessed) Overall population and HR - subpopulation Secondary: OS, ORR, CBR, Time to response, Safety, Duration of response
49 BOLERO-1/TRIO 019: PFS Full Popula4on (Inves4gator-assessment) Hurwitz S et al, SABCS 2014
50 Simultaneous blockade of HER2 and PI3K Trials combining an4her2 drugs and PI3K pathway inhibitors, including alpelisib (NCT ), taselisib (NCT ) and pic4lisib (NCT ) are underway In a phase 1b trial, the combina4on of buparlisib and trastuzumab was well tolerated and showed some ac4vity (ORR of 17%, 58% SD 6 weeks) in pa4ents with trastuzumab-pretreated HER2-posi4ve breast cancer 1 1 Saura C et al. Clin Cancer Res 2014;20:
51 Burstein H et al, J Clin Oncol 28:1301, 2010
52 A Randomized Phase II Trial of Nera4nib vs Lapa4nib /Capecitabine in HER2+ MBC Mar&n M et al, European Journal of Cancer, 49: 3763, 2013
53 A Study of Nera4nib Plus Capecitabine Versus Lapa4nib Plus Capecitabine in Pa4ents With HER2+ Metasta4c Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metasta4c Sefng NALA study(nala) Phase 3, double-blind trial in HER2+ metastatic BC patients with two or more lines of prior therapy N=600 Randomiza4on is stra4fied based on geographical regions. R A N D O M I Z E Neratinib 240 mg/day Capecitabine 1,500 mg/m 2 per day Lapatinib 1,250 mg/day Capecitabine 2,000 mg/m 2 per day
54 Presented by: Miguel Mar4n LoRusso P et al, AACR 2015
55 HERMIONE Study Schema NCT
56 Simultaneous blockade of the HER2 pathway HER2 HER3 VEGF PI3K RAS Cell membrane an4her2 + CDK 4/6 inhib. AKT PTEN RAF mtor MEK p27 Cyclin D Cyclin E MAPK Nucleus CDK 4/6 CDK 2 G1 S Studies of Palbociclib and Abemaciclib In metasta4c HER2 posi4ve cancer
57 Immune signature predicts benefit of adjuvant trastuzumab in N9831 Not immune signature enriched Immune signature enriched Interac4on term P <.001 Perez E et al. JCO :701
58 Immune System as a Target Tumour Infiltra4ng Lymphocytes TILs have been shown to be prognos4c and predic4ve in HER2 posi4ve breast cancers Be er prognosis and response NeoAn4gens Increased muta4onal load appears to be associated with a response to immune modula4ng agents PDL1 and PD 1 inhibitors Checkpoint inhibitors responses in HER2 cancers
59
60 CCTG - IND 229 Trial Schema HER2+ MBC Must have had prior trastuzumab and pertuzumab Durvalumab q3w un4l PD Trastuzumab q3w x 6 Dose ranging phase to establish RP2D RP2D / Expansion cohort 10 pa4ents (at least 6 with paired biopsies pre and post treatment ) This is a mul4centre phase 1bexpansion study of durvalumab given to pa4ents with advanced/ recurrent HER-2 posi4ve metasta4c breast cancer (MBC) who are receiving treatment with trastuzumab. Following an ini4al dose-ranging phase to establish RP2D, a cohort expansion will involve paired biopsies. PI : Stephen Chia 60
61 Vaccines Several pep4de-based vaccines derived from the extracellular domain of HER2 under clinical test A randomized phase II trial of E75 showed a non-sta4s4cally significant increase in 5-y DFS in early breast cancer (90% vs 80%, p=0.08) 1 A phase III with E75 currently ongoing (NCT ) Dendri4c cell vaccines and vaccine/ trastuzumab combina4ons also under test
62 This is how most cancers are structured but we have not been able to see this un4l now A single tumor biopsy may not represent the complete molecular landscape of disease
63 Heterogeneous HER2 amplifica4on may be associated with reduced sensi4vity to HER2- directed therapy HER2-targeted Rx Gene4cally heterogeneous for HER2 Blue=HER2+ Red= HER2- Selec4on for HER2-nega4ve tumor cells 1. Wolff, A.C., et al. J Clin Oncol, Viale et al. Modern Pathology 2013
64 Summary Incredible progress in HER2 treatment 1 st line pertuzumab/trastuzumab/taxane 2 nd line TDM-1 Evidence of con4nued targe4ng of HER2 in advanced disease Improved survival in newer studies With increased dual therapy in early disease this may not be seen we will need new strategies in MBC We need to understand Resistance CNS disease Tumour heterogenieity Who needs aggressive treatment vs who will be well with trastuzumab/ct alone
65 Challenges Op4mal therapy strategies need to be tailored to the individual pa4ent Dura4on of therapy. Do we need to treat persons forever or can they have drug holidays? Delivering the therapy is our societal challenge
66 Even clear signs can be misleading
Targe:ng HER2 in Metasta:c Breast Cancer in 2014
Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationAdvanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD
Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS
More informationExpanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationNew Drug Development in HER2+ Breast Cancer
New Drug Development in HER2+ Breast Cancer Philippe Aftimos, M.D. Senior Research Physician Clinical Pharmacology Unit Institut Jules Bordet Background Amplification of HER2 occurs in approximately 20%
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationPROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationBreast cancer update. Iryna Kuchuk, MD Oncology department Meir Medical Center
Breast cancer update Iryna Kuchuk, MD Oncology department Meir Medical Center Overview Cancer Death Rates* Among Women, US,1930-2009 Factors Associated with Reduction In Breast Cancer Mortality Early
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationUpdate in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France
Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors
More informationSystemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven
Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,
More informationHer 2 Positive Advanced Breast Cancer: From Evidence to Practice
Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Sunil Verma MD, FRCP(C) Medical Director, Tom Baker Cancer Center Professor and Head, Department of Oncology Cumming School of Medicine,
More informationAdvances in the Management of Metastatic Her 2 Positive Breast Cancer
Advances in the Management of Metastatic Her 2 Positive Breast Cancer Sunil Verma MD, MSEd, FRCPC Medical Oncologist Research Lead, Division of Medical Oncology Chair, Breast Medical Oncology Sunnybrook
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More informationEmerging Agents in HER2-positive Disease. Mary Cianfrocca, DO Director, Breast Oncology Program Banner MD Anderson Cancer Center Gilbert, AZ
Emerging Agents in HER2-positive Disease Mary Cianfrocca, DO Director, Breast Oncology Program Banner MD Anderson Cancer Center Gilbert, AZ Signal Transduction by the HER Family and Potential Mechanisms
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Management of HER2+ MBC SOBO 2012 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for Women s Cancer
More informationHer 2 Positive Metastatic Breast Cancer
Her 2 Positive Metastatic Breast Cancer Alison Jones November 2013 Mrs Hermione Positive (then and now!) Diagnosed 2007 T2 N1 Mo ER ve; Her2 ve Mastectomy ANC; FEC/T Herceptin (12months) August 2010metastatic
More informationLo studio BOLERO-1 Quali potranno essere le future ricadute nella pratica clinica? Antonella Ferro UO Oncologia Medica Trento
Lo studio BOLERO-1 Quali potranno essere le future ricadute nella pratica clinica? Antonella Ferro UO Oncologia Medica Trento TRASTUZUMAB most important breakthrough in the management of BC Trastuzumab
More informationJosé Baselga, MD, PhD
i n t e r v i e w José Baselga, MD, PhD Dr Baselga is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center in New York, New York. Tracks 1-15 Track 1 Track 2 Track 3 Track 4 Track 5 Track 6 Track
More informationEnfermedad con sobreexpresión de HER-2 neu
Enfermedad con sobreexpresión de HER-2 neu Elsa Dalmau Parc Taulí Sabadell. Hospital Universitari. Enfermedad con sobreexpresión de HER-2 neu ÍNDICE Neoadyuvancia Adyuvancia Enfermedad avanzada Enfermedad
More informationPIK3CA Mutations in HER2-Positive Breast Cancer
2016.4.29. GBCC PIK3CA Mutations in HER2-Positive Breast Cancer Seock-Ah Im, MD, PhD. Department of Internal Medicine Seoul National University Hospital Contents Introduction TCGA data HER2 signaling pathway
More informationKarcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski
Karcinom dojke PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski MBC: HER2 PHEREXA: Study Design Multicenter, randomized, open-label phase III trial Stratified by prior CNS disease,
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2017 Relative Risk HER2-positive Breast
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2018 HER2-positive Breast Cancer Adjuvant
More informationNuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Prima linea di trattamento
Nuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Prima linea di trattamento Prof. Sabino De Placido Dip. di Endocrinologia ed Oncologia
More information2014 San Antonio Breast Cancer Symposium Review
2014 San Antonio Breast Cancer Symposium Review HER2 Positive Disease 01-10-2015 Elisavet Paplomata, MD Assistant Professor Hematology & Medical Oncology Emory University Winship Cancer Institute S6-01
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationSystemic therapy for HER2+ Advanced Breast Cancer
Systemic therapy for HER2+ Advanced Breast Cancer F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESMO Board of Directors & NR Committee Chair ESO Breast Cancer Program
More informationDennis J Slamon, MD, PhD
I N T E R V I E W Dennis J Slamon, MD, PhD Dr Slamon is Professor of Medicine, Chief of the Division of Hematology/Oncology and Director of Clinical and Translational Research at UCLA s David Geffen School
More informationDisease Update: Metastatic Breast Cancer
Disease Update: Metastatic Breast Cancer Aimee Faso, PharmD, BCOP, CPP Oncology Clinical Specialist, GI/Breast UNC Hospitals and Clinics August 2015 Objectives Identify treatment choices of metastatic
More information非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
More informationTreatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
More informationChallenges and Success: Treatment of Metastatic Breast Cancer 2012
Challenges and Success: Treatment of Metastatic Breast Cancer 2012 Hope S. Rugo University of California San Francisco Helen Diller Family Comprehensive Cancer Center This presentation is the intellectual
More informationDEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO CÁNCER DE MAMA HER 2 POSITIVO
DEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO CÁNCER DE MAMA HER 2 POSITIVO DEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationRIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive
More informationSessione 4: La malattia metastatica. La malattia HER2-positiva: strategia terapeutica nella pratica clinica e il futuro G.
Sessione 4: La malattia metastatica La malattia HER2-positiva: strategia terapeutica nella pratica clinica e il futuro G. RICCIARDI UOC Oncologia Medica, A.O. Papardo, Messina Dir. Prof. V. Adamo giusyricciardi81@hotmail.it
More informationPresent and emerging treatment options in Her-2/neu overexpressing metastatic breast cancer
Present and emerging treatment options in Her-2/neu overexpressing metastatic breast cancer Christoph C. Zielinski Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center,
More informationHER2 Biology and Treatment in Breast Cancer
HER2 Biology and Treatment in Breast Cancer Sandra M. Swain, MD, FACP Director, Washington Cancer Institute Washington Hospital Center Professor of Medicine Georgetown University Washington DC Off-Label
More informationHER2 Positive Breast Cancer
HER2 Positive Breast Cancer Charles E. Geyer, Jr. MD, FACP Professor of Medicine Division of Hematology, Oncology and Palliative Care Virginia Commonwealth University Associate Director of Clinical Research
More informationMetastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
More informationPI3K/AKT/mTOR Inhibitors in Breast Cancer
PI3K/AKT/mTOR Inhibitors in Breast Cancer Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore Global Breast Cancer Conference 2015 Outline Overview of PI3K/Akt/mTOR Pathway Rationale
More informationTargeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine
2016.04.30 GBCC Education Symposium Targeting CDK 4/6 Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine Contents Cyclins -CDKs in cell cycle control CDK 4/6 in breast cancer Preclinical
More informationMEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014
MEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014 Dr Thomas Yau Clinical Assistant Professor MBBS(HK), MRCP (UK), FHKCP (Med Onc), FHKAM( Medicine), FRCP(London) Queen Mary Hospital The University of Hong Kong
More informationASCO and San Antonio Updates
ASCO and San Antonio Updates 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Breakthroughs
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationResistance to anti-her2 therapies. Service d Oncologie Médicale
Resistance to anti-her2 therapies Pr David Khayat Service d Oncologie Médicale Groupe Hospitalier Pitié Salpêtrière -Paris Disclosure statment Trastuzumab in HER2+ MBC A major impact but resistance will
More informationNovel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
More informationPost-ESMO 2012: Tamara Rordorf Klinik für Onkologie UniversitätsSpital Zürich T.Rordorf, SAMO Luzern 1
Post-ESMO 2012: Breast Cancer Tamara Rordorf Klinik für Onkologie UniversitätsSpital Zürich 1 Neoadjuvant treatment (in Her-2 positive disease) neoadjuvant trials abstracts: breast sparing surgery, biomarkers,
More informationFirst-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study
First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study Abstract LBA1 Hortobagyi GN, Stemmer SM, Burris HA,
More informationEndocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationCancer du sein métastatique et amélioration de la survie Pr. X. Pivot
Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationPage. Objectives: Hormone Therapy Resistance: Challenges and Opportunities. Research Support From Merck
Hormone Therapy Resistance: Challenges and Opportunities Pamela. N. Munster, MD University of California, San Francisco Financial Disclosures Research Support From Merck Objectives: Understanding the current
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationPro: Hormone Therapy in HR positive MBC is the preferred option!
Pro: Hormone Therapy in HR positive MBC is the preferred option! Alexandru Eniu, MD, PhD Medical Oncologist Head, Day Hospital Unit Department of Breast Tumors Cancer Institute Ion Chiricuţă Cluj-Napoca,
More informationHighlitghs in MBC First and second line endocrine treatments. Antonio Frassoldati Oncologia Clinica Ferrara
Highlitghs in MBC First and second line endocrine treatments Antonio Frassoldati Oncologia Clinica Ferrara Which clinical scenario have to face First line therapy with today? Untreated metastatic breast
More information10/15/2012. Overcoming Endocrine Therapy Resistance. The Problem in ER+ Tumors is Endocrine Therapy Resistance
Overcoming Endocrine Therapy Resistance Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Slide Credits: Hope Rugo, MD The Problem in ER+ Tumors is Endocrine Therapy Resistance
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationMetastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2. - Valentina Sini -
Metastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2 - Valentina Sini - Metastatic Breast Cancer ER- Her2-20% ER- Her2+ ER+ Her2+ 5% 15% ER+ Her2- ER+ Her2+ ER- Her2+
More informationEndocrine treatment might NOT be the preferred option in Hrpos MBC. Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015
Endocrine treatment might NOT be the preferred option in Hrpos MBC Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015 Overall survival not improved by the AI treatment Benefit in
More informationPharmacology Updates in Breast Cancer Chris Vaklavas, M.D.
Pharmacology Updates in Breast Cancer Chris Vaklavas, M.D. Assistant Professor Department of Medicine, Division of Hematology/Oncology University of Alabama at Birmingham NP2540M 1802 6th Avenue South
More informationThe Role of Angiogenesis Inhibition in Breast Cancer Today: Lessons Learned
The Role of Angiogenesis Inhibition in Breast Cancer Today: Lessons Learned Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education UCSF Helen Diller Family Comprehensive
More informationCáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre
Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre Recurrence of HER2-positive breast cancer (A) Time to
More informationSYSTEMIC THERAPY FOR HER-2+ ABC
SYSTEMIC THERAPY FOR HER-2+ ABC F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board of Directors & NR Committee Chair EORTC
More informationPost-ASCO 2017 Cancer du sein Triple Négatif
Post-ASCO 217 Cancer du sein Triple Négatif A.Ladjeroud, K.Bouzid Centre Pierre et Marie Curie- Alger Oran, 3 Septembre 217 Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationTRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
More informationMETRIC Study Key Eligibility Criteria
The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationExpert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer. Reference Slides
Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer Reference Slides Overview BRCA Mutations and Breast Cancer Patients with BRCA mutations have an estimated 55% to 65% cumulative
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center
Novel Preoperative Therapies for HER2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center Key Findings to Date in the Neoadjuvant Therapy of HER2+
More informationChemotherapy for Advanced Gastric Cancer
Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,
More informationRuth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory University, Chief of
Endocrine Therapy of Advanced Breast Cancer School of Breast Oncology November 9 th 2013 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology,
More informationNew chemotherapy drugs in metastatic breast cancer. Guy Jerusalem, MD, PhD
New chemotherapy drugs in metastatic breast cancer Guy Jerusalem, MD, PhD MBC Patients survival over time Median survival increases over time, but is still measured in months This is not yet a chronic
More informationPolicy No: dru281. Medication Policy Manual. Date of Origin: September 24, Topic: Perjeta, pertuzumab. Next Review Date: May 2015
Medication Policy Manual Topic: Perjeta, pertuzumab Committee Approval Date: May 9, 2014 Policy No: dru281 Date of Origin: September 24, 2012 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT
More informationInnovations In The Management Of
Innovations In The Management Of HER2+ Breast Cancer Dr. Sandeep Goyle Consultant Medical Oncologist Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute Mumbai, India Introduction - Self
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationOptimizing anti-her-2 therapies for ABC Potential role of immunotherapy. Javier Cortes, Ramon y
Optimizing anti-her-2 therapies for ABC Potential role of immunotherapy Javier Cortes, Ramon y Cajal University Hospital, Madrid, Spain Vall d Hebron Institute of Oncology (VHIO), Medica Scientia Innovation
More informationTarget biologico e meccanismo d azione dei farmaci anti-her2: il continuum dal setting Neoadiuvante alla malattia metastatica
Target biologico e meccanismo d azione dei farmaci anti-her2: il continuum dal setting Neoadiuvante alla malattia metastatica Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental
More informationOpen Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
More informationMedia Release. Basel, 3 June 2012
Media Release Basel, 3 June 2012 Roche s targeted investigational breast cancer medicine, trastuzumab emtansine (T-DM1), reduced the risk of cancer worsening or death by 35 percent in pivotal phase III
More informationBreast : ASCO Abstracts for Review
Breast : ASCO 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Abstracts for Review Prevention Neoadjuvant Metastatic Brain mets LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar The opportunity of the neoadjuvant approach L. Gianni, Milan, I XII Michelangelo Foundation Seminar Milano, October 12, 2012 The opportunity of the neoadjuvant approach
More informationLAPATINIB-Resistance to small Molecule ErbB2 Tyrosine Kinase Inhibitor (TKI)
LAPATINIB-Resistance to small Molecule ErbB2 Tyrosine Kinase Inhibitor (TKI) Prim Mr Sc Dr Suzana Vasović Institute for oncology and radiology of Serbia UMOS, X Conference, 16.05.2015 Belgrade How do we
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationIl trattamento medico
III Sessione: La malattia in fase avanzata Il trattamento medico Emilio Bria Oncologia, Dipartimento di Medicina, Università di Verona, Azienda Ospedaliera Universitaria Integrata Verona emilio.bria@univr.it
More information